VTGN - ビスタジェン・セラピュ―ティクス (VistaGen Therapeutics Inc.) ビスタジェン・セラピュ―ティクス

 VTGNのチャート


 VTGNの企業情報

symbol VTGN
会社名 VistaGen Therapeutics Inc (ビスタジェン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ビスタジェン・セラピューティクス(VistaGen Therapeutics Inc.)はバイオテクノロジーの企業である。同社はヒト多能性幹細胞技術(hPSC技術)に従事する。同社は薬物救助、予測毒性学および薬物代謝のスクリーニングにおいてhPSC技術を応用している。同社の製品は「CardioSafe 3D」「LiverSafe 3D」「AV-101」を含む。同社は毒性と非毒性の両方の生体内心臓への影響を予測するための三次元(3D)ビトロバイオアッセイ系のCardioSafe 3Dの小分子薬剤候補を、動物と人間でのテストのかなり前に開発した。同社は、多能性幹細胞由来の成熟ヒト肝細胞を利用して肝臓毒性および薬物代謝の問題を評価するための3Dビトロバイオアッセイ系のLiverSafe 3Dを開発・検証している。AV-101は数十億ドルの神経疾患・障害市場を目指す経口投与可能な低分子プロドラッグ候補である。   ビスタジェン・セラピュ―ティクスは米国のバイオ医薬品企業。臨床ステ―ジで、中枢神経系疾患やがんに対する治療法の開発・商業化に従事する。同社は幹細胞技術プラットフォ―ムを利用し、薬物となる化学物質を特定し候補薬を開発する。主要製品候補「AV-101」は鬱病の治療薬である。本社はカリフォルニア州サウス・サンフランシスコ。   VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
本社所在地 343 Allerton Avenue South San Francisco CA 94080 USA
代表者氏名 H. Ralph Snodgrass H.ラルフ・スノッドグラス
代表者役職名 President Chief Scientific Officer Director
電話番号 +1 650-577-3600
設立年月日 38626
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 9人
url www.vistagen.com
nasdaq_url https://www.nasdaq.com/symbol/vtgn
adr_tso
EBITDA EBITDA(百万ドル) -16.07700
終値(lastsale) 1.82
時価総額(marketcap) 46984419.3
時価総額 時価総額(百万ドル) 47.75889
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 40.72409
当期純利益 当期純利益(百万ドル) -17.55090
決算概要 決算概要 BRIEF: For the three months ended 30 June 2018 Vistagen Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 79% to $4.5M. Higher net loss reflects Research and development increase from $1.1M to $2.7M (expense) General and administrative increase of 26% to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.28 to -$0.20.

 VTGNのテクニカル分析


 VTGNのニュース

   VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia  2020/06/25 12:00:00 PR Newswire
/PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression…
   VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview  2020/02/13 21:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced financial…
   VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients  2020/01/30 13:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced that its…
   VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans  2019/12/19 13:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif. and HOUSTON, Dec. 19, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, and Baylor College of…
   VistaGen Up on Fast Track Designation for Anxiety Disorder Drug  2019/12/11 09:06:00 Zacks Investment Research
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.
   VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia  2020/06/25 12:00:00 PR Newswire
/PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression…
   VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview  2020/02/13 21:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced financial…
   VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients  2020/01/30 13:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced that its…
   VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans  2019/12/19 13:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif. and HOUSTON, Dec. 19, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, and Baylor College of…
   VistaGen Up on Fast Track Designation for Anxiety Disorder Drug  2019/12/11 09:06:00 Zacks Investment Research
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.
   VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia  2020/06/25 12:00:00 PR Newswire
/PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression…
   VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview  2020/02/13 21:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced financial…
   VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients  2020/01/30 13:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced that its…
   VistaGen and Baylor College of Medicine Announce Successful Results of First-Step Target Engagement Study with VistaGen's AV-101 Focused on Treating Suicidal Ideation in Veterans  2019/12/19 13:30:00 PR Newswire
SOUTH SAN FRANCISCO, Calif. and HOUSTON, Dec. 19, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, and Baylor College of…
   VistaGen Up on Fast Track Designation for Anxiety Disorder Drug  2019/12/11 09:06:00 Zacks Investment Research
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.

 関連キーワード  (医薬品 米国株 ビスタジェン・セラピュ―ティクス VTGN VistaGen Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)